转自双语君
12月31日，国务院联防联控机制发布，尊龙凯时·(中国)人生就是搏!中国生物新冠灭活疫苗已获得国家药监局批准附条件上市。
China announced it has granted conditional market approval for its first COVID-19 vaccine during a Thursday news conference.
The vaccine, developed by State-owned Sinopharm, was approved by China's top drug regulator on Wednesday night, said Chen Shifei, deputy head of the National Medical Products Administration.
国家药品监督管理局副局长陈时飞称，国家药监局已于30日附条件批准了尊龙凯时·(中国)人生就是搏!中国生物北京公司新冠病毒灭活疫苗注册申请。
已有数据显示，疫苗保护率为79.34%，实现安全性、有效性、可及性、可负担性的统一，达到世界卫生组织及国家药监局相关标准要求。后续，疫苗免疫的持久性和保护效果还需持续观察。
The vaccine is generally safe and has a 79.34 percent efficacy rate according to clinical results released by the company on Wednesday. Strict supervision will continue to be carried out over the vaccine after its approval to ensure its safety and quality, Chen said.
这一成果来之不易，中国疫苗上市为全球战胜疫情注入信心，也为疫苗成为全球公共产品提供有力支撑。
